CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: A report of two cases and analysis of CD30 expression-Reference-Cited by-同舟云学术

CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: A report of two cases and analysis of CD30 expression

Published:2014-05-30 Issue:3 Volume:110 Page:258-264
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J. Surg. Oncol.

Author:

Gill Kamraan¹,Ariyan Charlotte²,Wang Xuan²,Brady Mary Sue²,Pulitzer Melissa¹

Affiliation:

1. Department of Pathology; Memorial Sloan Kettering Cancer Center; New York New York

2. Department of Surgery; Memorial Sloan Kettering Cancer Center; New York New York

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.23636/fullpdf

Reference46 articles.

1. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit;Creech;Ann Surg,1958

2. Management of in-transit melanoma of the extremity with isolated limb perfusion;Fraker;Curr Treat Options Oncol,2004

3. Predicting disease progression after regional therapy for in-transit melanoma;Lidsky;JAMA Surg,2013

4. Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs;Thompson;World J Surg,1992

5. Current trends in regional therapy for melanoma: Lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution;Raymond;J Am Coll Surg,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. scConnect: a method for exploratory analysis of cell–cell communication based on single-cell RNA-sequencing data;Bioinformatics;2021-05-11

2. Case 22. Infusion-related CD30-positive lymphomatoid drug eruption secondary to melphalan;Cutaneous Lymphomas;2021

3. Primary cutaneous anaplastic large cell lymphoma;Journal of Cutaneous Pathology;2017-04-25

4. Dactinomycin/melphalan;Reactions Weekly;2014-09